A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines

References

• Cohen O, Knoll M, O‘Brien K, Ramakrishnan M, Constenla D, Privor-Dumm L, Buss-Younkin J, Farrar J, Pilishvili T, Whitney C. et al. Pneumococcal Conjugate Vaccine (PCV) product assessment; 2017 [accessed 2017 Sept 30]. https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf.
   Google Scholar
• Centers for Disease Control. Pneumococcal disease; 2015 [accessed 2017 Sept 30]. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.
   Google Scholar
• World Health Organization. Pneumococcal disease; 2016 [accessed 2017 Sept 30]. http://www.who.int/ith/diseases/pneumococcal/en/.
   Google Scholar
• World Health Organization. Immunization, vaccines and biologicals. pneumococcal disease; 2011 [accessed 2017 Sept 30]. http://www.who.int/immunization/topics/pneumococcal_disease/en/.
   Google Scholar
• Afonso ET, Minamisava R, Bierrenbach AL, Escalante JJ, Alencar AP, Domingues CM, Morais-Neto OL, Toscano CM, Andrade AL. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis. 2013;19:589–97. doi:10.3201/eid1904.121198.
   PubMed Web of Science ®Google Scholar
• Kellner J. Update on the success of the pneumococcal conjugate vaccine. Paediatr Child Health. 2011;16:233–40.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal vaccines WHO position paper–2012. Wkly Epidemiol Rec. 2012;87:129–44.
   PubMedGoogle Scholar
• National Advisory Committee on Immunization. Statement on recommended use of pneumococcal conjugate vaccine. Can Commun Dis Rep. 2002 January 15;28:1–32.
   Google Scholar
• European Medicines Agency. Synflorix, INN-Pneumococcal polysaccharide conjugate vaccine (adsorbed)-annex1; 2018 [accessed 2017 Sept 30]. https://www.ema.europa.eu/en/documents/product-information/synflorix-epar-product-information_en.pdf.
   Google Scholar
• GlaxoSmithKline Inc. Synflorix product monograph, Canada; 2018 [accessed 2017 Sept 30]. https://ca.gsk.com/media/591956/synflorix.pdf.
   Google Scholar
• Pfizer Canada Inc. Prevnar 13 product monograph, Canada; 2015 [accessed 2017 Sept 30]. https://www.pfizer.ca/sites/g/files/g10028126/f/201601/Prevnar_13_PM_189931_22Dec2015_E.pdf.
   Google Scholar
• de Oliveira LH, Camacho LA, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American Countries: a systematic review. PLoS One. 2016;11:e0166736. doi:10.1371/journal.pone.0166736.
   PubMed Web of Science ®Google Scholar
• Ewald H, Briel M, Vuichard D, Kreutle V, Zhydkov A, Gloy V. The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials. Dtsch Arztebl Int. 2016;113:139–46. doi:10.3238/arztebl.2016.0139.
   PubMed Web of Science ®Google Scholar
• Kanters S, Ford N, Druyts E, Thorlund K, Mills EJ, Bansback N. Use of network meta-analysis in clinical guidelines. Bull World Health Organ. 2016;94:782–84. doi:10.2471/BLT.16.174326.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Zarin W, Cardoso R, Veroniki AA, Khan PA, Nincic V, Ghassemi M, Warren R, Sharpe JP, Page AV, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. Bmj. 2018;363:k4029. doi:10.1136/bmj.k4029.
   PubMedGoogle Scholar
• Takeuchi M. Bayesian network meta-analysis suggests a similar effectiveness between a monovalent and a pentavalent rotavirus vaccine: a preliminary report of re-analyses of data from a Cochrane database systematic review. Hum Vaccin Immunother. 2014;10:1421–24. doi:10.4161/hv.28284.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr. 2002;161(Suppl 2):S127–31. doi:10.1007/s00431-002-1064-z.
   PubMedGoogle Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser permanente vaccine study center group. Pediatr Infect Dis J. 2000;19:187–95.
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002;21:182–86.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11:e1001657. doi:10.1371/journal.pmed.1001657.
   PubMed Web of Science ®Google Scholar
• Andrews N, Waight PA, Borrow R, Ladhani S, George RC, Slack MP, Miller E. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS One. 2011;6:e28435. doi:10.1371/journal.pone.0028435.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14:839–46. doi:10.1016/S1473-3099(14)70822-9.
   PubMed Web of Science ®Google Scholar
• De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, Farley MM, Harrison LH, Lynfield R, Bennett NM, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine. 2012;30:4067–72. doi:10.1016/j.vaccine.2012.04.017.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:9127–31. doi:10.1016/j.vaccine.2011.09.112.
   PubMed Web of Science ®Google Scholar
• Ruckinger S, van der Linden M, Reinert RR, von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: an analysis using the indirect cohort method. Vaccine. 2010;28:5012–16. doi:10.1016/j.vaccine.2010.05.021.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imohl M. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11:e0161257. doi:10.1371/journal.pone.0161257.
   PubMed Web of Science ®Google Scholar
• Verani JR, Domingues CM, de Moraes JC. Brazilian pneumococcal conjugate vaccine effectiveness study group. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine. 2015;33:6145–48. doi:10.1016/j.vaccine.2015.10.007.
   PubMed Web of Science ®Google Scholar
• Barricarte A, Castilla J, Gil-Setas A, Torroba L, Navarro-Alonso JA, Irisarri F, Arriazu M. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis. 2007;44:1436–41. doi:10.1086/516779.
   PubMed Web of Science ®Google Scholar
• Ciruela P, Soldevila N, Hernandez S, Selva L, de Sevilla MF, Garcia-Garcia JJ, Moraga F, Planes AM, Munoz-Almagro C, Dominguez A. Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes. Vaccine. 2013;31:960–66. doi:10.1016/j.vaccine.2012.11.102.
   PubMed Web of Science ®Google Scholar
• Cohen C, von Mollendorf C, de Gouveia L, Naidoo N, Meiring S, Quan V, Nokeri V, Fortuin-de Smit M, Malope-Kgokong B, Moore D, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in South Africa: a matched case-control study. Clin Infect Dis. 2014;59:808–18. doi:10.1093/cid/ciu431.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J. 2010;29:546–49. doi:10.1097/INF.0b013e3181cffa2a.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33:2684–89. doi:10.1016/j.vaccine.2015.04.005.
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC. Brazilian pneumococcal conjugate vaccine effectiveness study group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2:464–71. doi:10.1016/S2213-2600(14)70060-8.
   PubMed Web of Science ®Google Scholar
• Dominguez A, Ciruela P, Garcia-Garcia JJ, Moraga F, de Sevilla MF, Selva L, Coll F, Munoz-Almagro C, Planes AM, Codina G, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7–59 months. A matched case-control study. Vaccine. 2011;29:9020–25. doi:10.1016/j.vaccine.2011.09.034.
   PubMed Web of Science ®Google Scholar
• Fortunato F, Martinelli D, Cappelli MG, Cozza V, Prato R. Impact of Pneumococcal Conjugate Universal Routine Vaccination on Pneumococcal Disease in Italian Children. J Immunol Res. 2015;2015:206757. doi:10.1155/2015/206757.
   PubMed Web of Science ®Google Scholar
• Guevara M, Barricarte A, Torroba L, Herranz M, Gil-Setas A, Gil F, Bernaola E, Ezpeleta C, Castilla J. Working group for surveillance of the pneumococcal invasive disease in Navarra. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study. Euro Surveill. 2016;21.
   PubMedGoogle Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4:399–406. doi:10.1016/S2213-2600(16)00052-7.
   PubMed Web of Science ®Google Scholar
• Picon T, Alonso L, Garcia Gabarrot G, Speranza N, Casas M, Arrieta F, Camou T, Rosa R, De Oliveira LH, Verani JR. Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: an evaluation using existing data. Vaccine. 2013;31(Suppl 3):C109–13. doi:10.1016/j.vaccine.2013.01.059.
   PubMedGoogle Scholar
• Su WJ, Lo HY, Chang CH, Chang LY, Chiu CH, Lee PI, Lu CY, Hsieh YC, Lai MS, Lin TY. Effectiveness of pneumococcal conjugate vaccines of different valences against invasive pneumococcal disease among children in taiwan: a nationwide study. Pediatr Infect Dis J. 2016;35:e124–33. doi:10.1097/INF.0000000000001054.
   PubMed Web of Science ®Google Scholar
• von Mollendorf C, Cohen C, de Gouveia L, Naidoo N, Meiring S, Quan V, Lindani S, Moore DP, Reubenson G, Moshe M, et al. Risk factors for invasive pneumococcal disease among children less than 5 years of age in a high HIV prevalence setting, South Africa, 2010 to 2012. Pediatr Infect Dis J. 2015;34:27–34. doi:10.1097/INF.0000000000000484.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495–502. doi:10.1016/S0140-6736(06)69637-2.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Zell ER, Farley MM, Schaffner W, Lynfield R, Nyquist AC, Vazquez M, Bennett NM, Reingold A, Thomas A, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics. 2010;126:e9–17. doi:10.1542/peds.2009-2150.
   PubMed Web of Science ®Google Scholar
• WHO/World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. Technical Report Series; 2005:35.
   Google Scholar
• Comité sur l’immunisation du Québec (CIQ). Scientific advisory on the optimal schedule for childhood immunization against pneumococcal disease in Québec; 2017 [accessed 2017 Sept 30]. https://www.inspq.qc.ca/sites/default/files/publications/2379_opinion_optimal_schedule_childhood_immunization_pneumococcal_disease.pdf.
   Google Scholar
• Naucler P, Galanis I, Morfeldt E, Darenberg J, Ortqvist A, Henriques-Normark B. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin Infect Dis. 2017;65:1780–89. doi:10.1093/cid/cix685.
   PubMed Web of Science ®Google Scholar
• Merck. Press release. [accessed 2017 Sept 30]. https://investors.merck.com/news/press-release-details/2018/Merck-Announces-First-Phase-Three-Studies-for-PCV-15-V114-Its-Investigational-Pneumococcal-Disease-Vaccine/default.aspx.
   Google Scholar
• Merck. pipeline. [accessed 2017 Sept 30]. https://www.pfizer.com/science/vaccines/pipeline
   Google Scholar
• Jansen JP, Leahy J Disconnected or limited evidence in network meta-analysis: what else can be done? Presented at ISPOR 2017, Glasgow, Scotland 2017.
   Google Scholar
• Digitizeit (Computer software); 2018 [accessed 2017 Sept 30]. https://www.digitizeit.de/.
   Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]; 2011 [accessed 2017 Sept 30]. http://handbook.cochrane.org.
   Google Scholar
• Wells GA, Shea B, O‘Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2018 [accessed 2017 Sept 30]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:93. doi:10.1186/s12916-014-0141-2.
   PubMed Web of Science ®Google Scholar